← back to search

Shibao Feng

Fitbit (United States) · US
Area of research
Oncology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Multiple Myeloma Research and Treatments, Cancer Treatment and Pharmacology, and Fibroblast Growth Factor Research.
h-index
27
citations
3,908
works
84
NIH funding
primary concept
Medicine
email

Recent publications

Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy
Hepatology 2025cited by 10position: middledoi
MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH
Gut 2024cited by 36position: middledoi
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
New England Journal of Medicine 2023cited by 424position: middledoi
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
Haematologica 2020cited by 102position: middledoi
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial
Blood 2020cited by 36position: middledoi
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
The Lancet Oncology 2017cited by 401position: middledoi
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
The Lancet Oncology 2015cited by 842position: middledoi
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
Breast Cancer Research and Treatment 2012cited by 55position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Rohit Loomba · Indiana University – Purdue University Indianapolis3 papers (2023–2025)Mildred D. Gottwald · Fitbit (United States)3 papers (2023–2025)Maya Margalit · IDEA Bio-Medical (Israel)3 papers (2023–2025)Harris Siddiqi · University of California San Diego2 papers (2024–2025)Lisa Richards · The University of Texas at Austin2 papers (2024–2025)Egbert Madamba · Stanford University2 papers (2024–2025)Daniel Q. Huang · Second Affiliated Hospital of Xi'an Jiaotong University2 papers (2024–2025)Peter A. Kaufman · University of Vermont1 papers (2012–2012) · 1 papers (2012–2012)Denise A. Yardley · Lublin Oncology Center1 papers (2012–2012)Katja Weisel · National Institute Of Blood Disease and Bone Marrow Transplantation1 papers (2017–2017)Thierry Façon · Inserm1 papers (2017–2017)Claude B. Sirlin · Université de Montréal1 papers (2024–2024)Heinz Ludwig · Comprehensive Cancer Center Vienna1 papers (2017–2017)Cheng S. Quah · Principia Biopharma (United States)1 papers (2012–2012)Leonard Minuk · University of Manitoba1 papers (2017–2017)Meletios Α. Dimopoulos · Korea University1 papers (2017–2017)Robert Z. Orlowski · The University of Texas MD Anderson Cancer Center1 papers (2017–2017)Pierre Bédossa · Université Sorbonne Paris Nord1 papers (2023–2023)Donald J. Lazas · Tennessee Department of Health1 papers (2023–2023)